From: Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
Rituximab
Obinutuzumab
Rituximab vs obinutuzumab
Cell death (%)
p-value
JeKo-1
1.31. ± 0.26
0.024*
3.00 ± 1.02
0.012*
0.030*
REC-1
2.15 ± 0.85
0.029*
2.64 ± 1.31
0.038*
0.493